With the biopharmaceutical world still buzzing from the latest data presented at the American Society of Hematology meeting, we sat down with industry expert Ivan Kairatov to unpack the results that have sent one company's stock soaring. At the center of the discussion is TERN-701, an experimental
Allow me to introduce Ivan Kairatov, a distinguished biopharma expert whose innovative research and development work has significantly advanced our understanding of cellular signaling and protein interactions. With a profound focus on transporter regulation, Ivan has been at the forefront of
Imagine a world where a single drug could shift the trajectory of blood cancer treatment, offering hope to thousands battling chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). At the recent American Society of Hematology (ASH) meeting in Orlando, Eli Lilly thrust its BTK
Allow me to introduce Ivan Kairatov, a seasoned biopharma expert whose extensive background in technology and innovation has positioned him at the forefront of groundbreaking developments in genetic medicine. With years of experience in research and development, Ivan has been closely following the
Imagine a world where the most abundant immune cells in the human body, crucial for fighting infections, remain a mysterious black box to scientists and medical professionals. For too long, neutrophils—those rapid-response warriors of the immune system—have been just that, with their complex
Imagine a world where living to 100 is common, yet the decline of mind and body feels just as relentless as it does today—where longer life doesn’t mean slower aging. This paradox lies at the heart of a provocative critique by Dr. Dan Ehninger and Dr. Maryam Keshavarz, published in Genomic
